The treatment of children with posterior fossa brain tumours (PFBT) impacts their long term functional and imaging outcomes. This study aimed to evaluate academic achievement correlated with long-term sequelae after different PFBT treatment modalities. The study cohort consisted of 110 survivors (median age at diagnosis 10.1 years and median time of follow up 13.2 years) who completed hearing questionnaires, neurological assessment and MRI of the brain ≥5 years after the end of treatment. There were three treatment groups. A cisplatin group which underwent cisplatin chemotherapy, radiotherapy and surgery (medulloblastoma N = 40), a radiotherapy group which underwent radiotherapy and surgery (astrocytoma/ependymoma N = 30), and a surgery group (astrocytoma N = 40). Academic achievement was correlated to the age at diagnosis, ototoxicity, Karnofsky score (KS), and MRI findings (Fazekas Score (FS)- treatment related parenchymal changes). For a modelled age at diagnosis of five years, the cisplatin group had lower academic achievements compared to the radiotherapy (p = 0.028) and surgery (p = 0.014) groups. Academic achievements evaluated at a modelled age of 10 years at diagnosis did not significantly differ among the treatment groups. The cisplatin group exhibited a higher occurrence of ototoxicity than the radiotherapy (p<0.019) and surgery groups (p<0.001); however, there was no correlation between ototoxicity and academic achievements (p = 0.722) in older age at diagnosis. The radiotherapy group exhibited lower KS than the surgery group (p<0.001). KS significantly influenced academic achievements in all groups (p<0.000). The cisplatin group exhibited higher FS than the surgery group (p<0.001) while FS did not correlate with academic achievement (p = 0.399). Older age is a protective factor for academic achievements irrespective of a treatment modality.

Bioinformatics Centre Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Department of Paediatric Haematology and Oncology Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Department of Paediatric Neurology Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Department of Phoniatrics and Pedaudiology University Hospital Münster Münster Germany

Department of Radiology Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Pediatric Oncology and Hematology University Hospital for Children and Adolescents Lübeck Germany

Zobrazit více v PubMed

Brinkman TM, Bass JK, Li Z, Ness KK, Gajjar A, Pappo AS, et al. Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: Results from the St. Jude Lifetime Cohort Study. Cancer. 2015;121: 4053–4061. 10.1002/cncr.29604 PubMed DOI PMC

Rowe LS, Krauze AV, Ning H, Camphausen KA, Kaushal A. Optimizing the benefit of CNS radiation therapy in the pediatric population-PART 1: understanding and managing acute and late toxicities. Oncology. 2017;31: 182–188. PubMed

Armstrong GT, Conklin HM, Huang S, Srivastava D, Sanford R, Ellison DW, et al. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro Oncol. 2011; 13:223–234. 10.1093/neuonc/noq178 PubMed DOI PMC

Orgel E, O'Neil SH, Kayser K, Orgel E, O'Neil SH, Kayser K, et al. Effect of Sensorineural Hearing Loss on Neurocognitive Functioning in Pediatric Brain Tumor Survivors. Pediatr Blood Cancer. 2016; 63:527–534. 10.1002/pbc.25804 PubMed DOI PMC

Bass JK, Hua CH, Huang J, Onar-Thomas A, Ness KK, et al. Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer. J Clin Oncol. 2016; 34:1248–1255. 10.1200/JCO.2015.63.6738 PubMed DOI PMC

Scobioala S, Parfitt R, Matulat P, Ebrahimi F, Wolters H, Zehnhoff-Dinnesen A, et al. Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing: retrospective analysis of 29 medulloblastoma patients. Strahlentherapie und Onkologie. 2017; 193: 910–920. 10.1007/s00066-017-1205-y PubMed DOI

Rueckriegel SM, Driever PH, Bruhn H. Supratentorial neurometabolic alterations in pediatric survivors of posterior fossa tumors. Int J Radiat Oncol Biol Phys. 2012; 82:1135–1141. 10.1016/j.ijrobp.2011.04.017 PubMed DOI

Sleurs C, Deprez S, Emsell L, Lemiere J, Yuttebroeck A. Chemotherapy-induced neurotoxicity in pediatric solid non-CNS tumor patients: an update on current state of research and recommended future directions. Crit Rev Oncol Hematol. 2016; 103:37–48. 10.1016/j.critrevonc.2016.05.001 PubMed DOI

Khong PL, Leung LH, Fung AS, Daniel YT, Fong DQ, Dora LW, et al. White matter anisotropy in post-treatment childhood cancer survivors: preliminary evidence of association with neurocognitive function. J Clin Oncol. 2006; 24:884–889. 10.1200/JCO.2005.02.4505 PubMed DOI

Froklage FE, Oosterbaan LJ, Sizoo EM, Groot M, Bosma I, Sanchez E, et al. Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study. J Neurooncol. 2014; 116:387–394. 10.1007/s11060-013-1310-4 PubMed DOI

Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2:187–193. 10.1200/JCO.1984.2.3.187 PubMed DOI

Korlimarla A, Spiridigliozzi GA, Crisp K, et al. Novel approaches to quantify CNS involvement in children with Pompe disease. Neurology. 2020;95(6):e718–e732. 10.1212/WNL.0000000000009979 PubMed DOI PMC

Forbes K. MRI brain white matter change: spectrum of change—how we can grade?. J R Coll Physicians Edinb. 2017;47(3):271–275. 10.4997/JRCPE.2017.313 PubMed DOI

Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009; 101:946–958. 10.1093/jnci/djp148 PubMed DOI PMC

Musial-Bright L, Fengler R, Henze G, Driever PH. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. Childs Nerv Syst. 2011;27:407–413. 10.1007/s00381-010-1300-1 PubMed DOI

Orgel E, Jain S, Ji L, Pollick L, Si S, Finlay J, et al. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. Pediatr Blood Cancer. 2002; 58:953–958. 10.1002/pbc.23275 PubMed DOI

Duffner PK. Risk factors for cognitive decline in children treated for brain tumors. Eur J Paediatr Neurol. 2010;14:106–115. 10.1016/j.ejpn.2009.10.005 PubMed DOI

Tabori U, Sung L, Hukin J, Laperriere N, Crooks B, Carret AS, et al. Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a canadian pediatric brain tumor consortium study. Cancer. 2005;103:1874–1880. 10.1002/cncr.21003 PubMed DOI

Monje M, Fisher PG.Neurological complications following treatment of children with brain tumors. J Pediatr Rehabil Med. 2011;4:31–36. 10.3233/PRM-2011-0150 PubMed DOI PMC

Vargo M. Brain tumor rehabilitation. Am J Phys Med Rehabil. 2011;90: S50–S62. 10.1097/PHM.0b013e31820be31f PubMed DOI

Leung LH, Ooi GC, Kwong DL, Chan GC, Cao G, Kwong PL. White-matter diffusion anisotropy after chemo-irradiation: a statistical parametric mapping study and histogram analysis. Neuroimage. 2004; 21:261–268. 10.1016/j.neuroimage.2003.09.020 PubMed DOI

Lassaletta A, Bouffet E, Mabbott D, Kulkarni AV. Functional and neuropsychological late outcomes in posterior fossa tumors in children. Childs Nerv Syst. 2015; 31: 1877–1890. 10.1007/s00381-015-2829-9 PubMed DOI

Boman KK, Hovén E, Anclair M, Lannering B, Gustafsson G. Health and persistent functional late effects in adult survivors of childhood CNS tumours: a population-based cohort study. Eur J Cancer. 2009; 45:2552–2561. 10.1016/j.ejca.2009.06.008 PubMed DOI

Zou P, Mulhern RK, Butler RW, Li CS, Langston JW, Ogg RJ. BOLD responses to visual stimulation in survivors of childhood cancer. Neuroimage. 2005; 24: 61–69. 10.1016/j.neuroimage.2004.08.030 PubMed DOI

Khong PL, Leung LH, Chan GC, Kwong DL, Wong WH, Cao G, et al. White matter anisotropy in childhood medulloblastoma survivors: association with neurotoxicity risk factors. Radiology. 2005; 236: 647–652. 10.1148/radiol.2362041066 PubMed DOI

Shan ZY, Liu JZ, Glass JO, Gajjar A, Li CHS, Reddick WE. Quantitative morphologic evaluation of white matter in survivors of childhood medulloblastoma. Magn Reson Imaging. 2006; 24:1015–1022. 10.1016/j.mri.2006.04.015 PubMed DOI

Rueckriegel SM, Driever PH, Blankenburg F, Lüdemann L, Henze G, Bruhn H. Differences in supratentorial damage of white matter in pediatric survivors of posterior fossa tumors with and without adjuvant treatment as detected by magnetic resonance diffusion tensor imaging. Int J Radiat Oncol Biol Phys. 2010; 76:859–866. 10.1016/j.ijrobp.2009.02.054 PubMed DOI

Winick N. Neurocognitive outcome in survivors of pediatric cancer. Curr Opin Pediatr. 2011; 23: 27–33. 10.1097/MOP.0b013e32834255e9 PubMed DOI